<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo2400" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38919514</article-id><article-id pub-id-type="pmc">PMC11196240</article-id>
<article-id pub-id-type="doi">10.1002/deo2.400</article-id><article-id pub-id-type="publisher-id">DEO2400</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Endoscopic findings and outcomes of gastric mucosal changes relating to potassium&#x02010;competitive acid blocker and proton pump inhibitor therapy</article-title><alt-title alt-title-type="left-running-head">SHINOZAKI <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo2400-cr-0001" contrib-type="author" corresp="yes"><name><surname>Shinozaki</surname><given-names>Satoshi</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6935-4470</contrib-id><xref rid="deo2400-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>shinozaki-s@aqua.ocn.ne.jp</email></address></contrib><contrib id="deo2400-cr-0002" contrib-type="author"><name><surname>Osawa</surname><given-names>Hiroyuki</given-names></name><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo2400-cr-0003" contrib-type="author"><name><surname>Miura</surname><given-names>Yoshimasa</given-names></name><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="deo2400-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo2400-cr-0004" contrib-type="author"><name><surname>Nomoto</surname><given-names>Hiroaki</given-names></name><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo2400-cr-0005" contrib-type="author"><name><surname>Sakamoto</surname><given-names>Hirotsugu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2458-1693</contrib-id><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo2400-cr-0006" contrib-type="author"><name><surname>Hayashi</surname><given-names>Yoshikazu</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2393-639X</contrib-id><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo2400-cr-0007" contrib-type="author"><name><surname>Yano</surname><given-names>Tomonori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0160-432X</contrib-id><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo2400-cr-0008" contrib-type="author"><name><surname>Despott</surname><given-names>Edward J.</given-names></name><xref rid="deo2400-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="deo2400-cr-0009" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Hironori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3601-1153</contrib-id><xref rid="deo2400-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="deo2400-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Shinozaki Medical Clinic</institution>
<named-content content-type="country-part">Tochigi</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo2400-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Division of Gastroenterology</named-content>
<institution>Jichi Medical University</institution>
<named-content content-type="country-part">Tochigi</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo2400-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<named-content content-type="organisation-division">Division of Gastroenterology and Hepatology</named-content>
<institution>Nihon University School of Medicine</institution>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo2400-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Royal Free Unit for Endoscopy</named-content>
<institution>The Royal Free Hospital and UCL Institute for Liver and Digestive Health</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Satoshi Shinozaki, Shinozaki Medical Clinic, Utsunomiya, 6&#x02010;1&#x02010;13 Kiyoharadai, Utsunomiya, Tochigi, 321&#x02013;3232, Japan.<break/> Email: <email>shinozaki-s@aqua.ocn.ne.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="114">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e400</elocation-id><history>
<date date-type="rev-recd"><day>27</day><month>5</month><year>2024</year></date>
<date date-type="received"><day>30</day><month>4</month><year>2024</year></date>
<date date-type="accepted"><day>03</day><month>6</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e400.pdf"/><abstract><title>Abstract</title><p>Gastric mucosal changes associated with long&#x02010;term potassium&#x02010;competitive acid blocker and proton pump inhibitor (PPI) therapy may raise concern. In contrast to that for PPIs, the evidence concerning the safety of long&#x02010;term potassium&#x02010;competitive acid blocker use is scant. Vonoprazan (VPZ) is a representative potassium&#x02010;competitive acid blocker released in Japan in 2015. In order to shed some comparative light regarding the outcomes of gastric mucosal lesions associated with a long&#x02010;term acid blockade, we have reviewed six representative gastric mucosal lesions: fundic gland polyps, gastric hyperplastic polyps, multiple white and flat elevated lesions, cobblestone&#x02010;like gastric mucosal changes, gastric black spots, and stardust gastric mucosal changes. For these mucosal lesions, we have evaluated the association with the type of acid blockade, patient gender, <italic toggle="yes">Helicobacter pylori</italic> infection status, the degree of gastric atrophy, and serum gastrin levels. There is no concrete evidence to support a significant relationship between VPZ/PPI use and the development of neuroendocrine tumors. Current data also shows that the risk of gastric mucosal changes is similar for long&#x02010;term VPZ and PPI use. Serum hypergastrinemia is not correlated with the development of some gastric mucosal lesions. Therefore, serum gastrin level is unhelpful for risk estimation and for decision&#x02010;making relating to the cessation of these drugs in routine clinical practice. Given the confounding potential neoplastic risk relating to <italic toggle="yes">H. pylori</italic> infection, this should be eradicated before VPZ/PPI therapy is commenced. The evidence to date does not support the cessation of clinically appropriate VPZ/PPI therapy solely because of the presence of these associated gastric mucosal lesions.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo2400-kwd-0001">endoscopy</kwd><kwd id="deo2400-kwd-0002">gastroesophageal reflux disease</kwd><kwd id="deo2400-kwd-0003">potassium&#x02010;competitive acid blocker</kwd><kwd id="deo2400-kwd-0004">proton pump inhibitor</kwd><kwd id="deo2400-kwd-0005">vonoprazan</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="11"/><word-count count="7566"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo2400-sec-0010"><title>INTRODUCTION</title><p>The worldwide use of proton pump inhibitors (PPIs) is increasing and long&#x02010;term use of these drugs is also frequently required as maintenance therapy for gastroesophageal reflux disease (GERD). Long&#x02010;term use is also applied as a preventive strategy to reduce the risk of peptic ulceration and gastrointestinal bleeding in the context of non&#x02010;steroidal anti&#x02010;inflammatory drugs and low&#x02010;dose aspirin use.<xref rid="deo2400-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="deo2400-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Although <italic toggle="yes">Helicobacter pylori</italic> eradication decreases the risk of peptic ulceration, eradication success augments gastric acid secretion, and this may be associated with the occurrence of GERD. In Japan, the prevalence of <italic toggle="yes">H. pylori</italic> infection is decreasing, and this has been associated with a decrease in the prevalence of gastric atrophy.<xref rid="deo2400-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Active <italic toggle="yes">H. pylori</italic> infection is associated with diminished gastric acid secretion through associated dysfunction of parietal cells, and an increased presence of inflammatory cytokines within the gastric fundus. Therefore, <italic toggle="yes">H. pylori</italic> eradication increases gastric acid secretion through recovery of the H<sup>+</sup>/K<sup>+</sup>&#x02010;ATPase expression of parietal cells.<xref rid="deo2400-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>PPI therapy suppresses gastric acid secretion through inhibition of H<sup>+</sup>/K<sup>+</sup>&#x02010;ATPase. Although three decades have passed since the introduction of PPI therapy into general clinical practice in the United States, there are still unmet needs for the effective management of GERD; this is mainly due to insufficient acid suppression. Acid blockade by PPIs is largely influenced by the CYP2C19 genotype status, and the pH 4 holding time of PPIs is only about 12 h in patients who are extensive metabolizers.<xref rid="deo2400-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Notably, even double&#x02010;dose PPI therapy fails to control nocturnal acid breakthrough symptoms.<xref rid="deo2400-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> These patients also experience daytime heartburn because of an insufficient pH 4 holding time.<xref rid="deo2400-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo2400-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> These failings have spurred research into seeking alternative, more robust acid blockade.</p><p>Vonoprazan (VPZ), a potassium&#x02010;competitive acid blocker (PCAB), was subsequently developed by Takeda Pharmaceutical Company Limited; it entered clinical practice in Japan in 2015. Unlike PPIs, VPZ works through direct and reversible H<sup>+</sup>&#x02010;K<sup>+</sup> exchange in gastric parietal cells; its acid blockade is long&#x02010;lasting and not influenced by luminal acidity or the CYP2C19 genotype.<xref rid="deo2400-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="deo2400-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="deo2400-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Therefore, VPZ has a stronger and more stable acid suppressive effect as compared with PPIs. The intragastric pH 4 holding time is important in the treatment of GERD, <italic toggle="yes">H. pylori</italic> infection, and peptic ulcers. VPZ has been shown to have a significantly higher pH 4 holding time than esomeprazole or rabeprazole in <italic toggle="yes">H. pylori</italic>&#x02010;negative healthy volunteers.<xref rid="deo2400-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo2400-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> VPZ has also been shown to be useful for long&#x02010;term control of symptomatic GERD.<xref rid="deo2400-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo2400-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> It achieves superior outcomes over PPIs in patients with severe reflux esophagitis (Los Angeles grade C/D).<xref rid="deo2400-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> A recent systematic review also reported the superior effect of VPZ on nocturnal acid breakthrough as compared with PPIs.<xref rid="deo2400-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>To evaluate the long&#x02010;term safety of VPZ as compared with PPIs, the VISION (the Vonoprazan study In patients with eroSIve esophagitis to evaluate long&#x02010;term safety) study was conducted from 2016 to 2022. This open&#x02010;label randomized controlled prospective study included 135 patients treated with VPZ 10 or 20 mg once daily and 67 patients with lansoprazole 15 or 30 mg once daily for 5 years.<xref rid="deo2400-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> The VISION study excluded patients with current infection of <italic toggle="yes">H. pylori</italic> or a history of <italic toggle="yes">H. pylori</italic> eradication, and therefore we assume that patients with gastric atrophy were mostly excluded. The VISION study performed a histopathological evaluation of biopsies from included patients on a yearly basis.<xref rid="deo2400-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</p><p>Given the increasing concerns associated with long&#x02010;term acid suppression therapy, it is important to scientifically evaluate and understand the prevalence and features of any associated gastric mucosal changes. In contrast to that for PPIs, the evidence concerning the safety of long&#x02010;term PCAB use is scant. Although PCABs also include the drug tegoprazan,<xref rid="deo2400-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> any long&#x02010;term follow&#x02010;up data only relate to the use of VPZ. Therefore, in this review, we have focused on the long&#x02010;term safety and gastric mucosal changes associated with VPZ and PPI use (Table&#x000a0;<xref rid="deo2400-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="deo2400-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Six representative gastric lesions associated with vonoprazan /proton pump inhibitors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="3" style="border-bottom:solid 1px #000000" rowspan="1">Prevalence</th><th align="left" rowspan="2" colspan="1">Gender</th><th align="left" rowspan="2" colspan="1">
<italic toggle="yes">H. pylori</italic>
</th><th align="left" rowspan="2" colspan="1">Gastric atrophy</th><th align="left" rowspan="2" colspan="1">Hypergastrinemia</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">VPZ user</th><th align="left" rowspan="1" colspan="1">PPI user</th><th align="left" rowspan="1" colspan="1">Comparison</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fundic gland polyps</td><td align="left" rowspan="1" colspan="1">43%&#x02013;72%</td><td align="left" rowspan="1" colspan="1">14%&#x02013;85%</td><td align="left" rowspan="1" colspan="1">VPZ &#x0003c; PPI</td><td align="left" rowspan="1" colspan="1">M &#x0003c; F</td><td align="left" rowspan="1" colspan="1">No infection</td><td align="left" rowspan="1" colspan="1">None to mild</td><td align="left" rowspan="1" colspan="1">Not related</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric hyperplastic polyps</td><td align="left" rowspan="1" colspan="1">8%&#x02013;23%</td><td align="left" rowspan="1" colspan="1">9%&#x02013;12%</td><td align="left" rowspan="1" colspan="1">VPZ &#x0003e; PPI</td><td align="left" rowspan="1" colspan="1">M = F</td><td align="left" rowspan="1" colspan="1">Current infection</td><td align="left" rowspan="1" colspan="1">Moderate to severe</td><td align="left" rowspan="1" colspan="1">Related?</td></tr><tr><td align="left" rowspan="1" colspan="1">Multiple white and flat elevated lesions</td><td align="left" rowspan="1" colspan="1">8%&#x02013;30%</td><td align="left" rowspan="1" colspan="1">13%&#x02013;49%</td><td align="left" rowspan="1" colspan="1">VPZ &#x0003c; PPI</td><td align="left" rowspan="1" colspan="1">M &#x0003c; F</td><td align="left" rowspan="1" colspan="1">History of eradication</td><td align="left" rowspan="1" colspan="1">?</td><td align="left" rowspan="1" colspan="1">Not related</td></tr><tr><td align="left" rowspan="1" colspan="1">Cobblestone&#x02010;like gastric mucosal changes</td><td align="left" rowspan="1" colspan="1">9%&#x02013;22%</td><td align="left" rowspan="1" colspan="1">11%&#x02013;35%</td><td align="left" rowspan="1" colspan="1">VPZ = PPI</td><td align="left" rowspan="1" colspan="1">?</td><td align="left" rowspan="1" colspan="1">?</td><td align="left" rowspan="1" colspan="1">None to mild</td><td align="left" rowspan="1" colspan="1">Not related</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric black spots</td><td align="left" rowspan="1" colspan="1">8%</td><td align="left" rowspan="1" colspan="1">13%&#x02013;16%</td><td align="left" rowspan="1" colspan="1">VPZ &#x0003c; PPI</td><td align="left" rowspan="1" colspan="1">?</td><td align="left" rowspan="1" colspan="1">History of eradication</td><td align="left" rowspan="1" colspan="1">?</td><td align="left" rowspan="1" colspan="1">Not related</td></tr><tr><td align="left" rowspan="1" colspan="1">Stardust gastric mucosal changes</td><td align="left" rowspan="1" colspan="1">5%&#x02013;68%</td><td align="left" rowspan="1" colspan="1">11%&#x02013;12%</td><td align="left" rowspan="1" colspan="1">VPZ &#x0003e; PPI</td><td align="left" rowspan="1" colspan="1">M &#x0003c; F</td><td align="left" rowspan="1" colspan="1">?</td><td align="left" rowspan="1" colspan="1">None to mild</td><td align="left" rowspan="1" colspan="1">Related?</td></tr></tbody></table><table-wrap-foot><fn id="deo2400-tbl1-note-0001"><p>Abbreviations: F, female; <italic toggle="yes">H. pylori</italic>, <italic toggle="yes">Helicobacter pylori</italic>; M, male; PPI, proton pump inhibitor; VPZ, vonoprazan.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><sec id="deo2400-sec-0020"><title>Histopathology of the stomach during VPZ/PPI therapy</title><p>Long&#x02010;term PPI use promotes cystic dilation of fundic glands and foveolar epithelial hyperplasia.<xref rid="deo2400-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Enterochromaffin&#x02010;like (ECL) cell proliferation caused by long&#x02010;term PPI use is also well demonstrated by a systematic review.<xref rid="deo2400-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> This same systematic review showed no evidence of the development of dysplastic or neoplastic changes in association with PPI use.<xref rid="deo2400-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Parietal cell protrusion is recognized as prominent intraluminal protrusions, and is associated with a narrow and serrated glandular lumen (sparse secretory canaliculi).<xref rid="deo2400-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> These changes are proportionate to the duration of PPI therapy. In the VISION study, any ECL cell hyperplasia was similar for the VPZ and PPI groups at 5 years.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p></sec><sec id="deo2400-sec-0030"><title>Fundic gland polyps</title><p>Fundic gland polyps account for 77% of all gastric polyps.<xref rid="deo2400-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Fundic gland polyps usually develop in multiple sites on the gastric fundus and corpus and have a sessile morphology with a smooth translucent surface (Figure&#x000a0;<xref rid="deo2400-fig-0001" ref-type="fig">1a</xref>). The association of long&#x02010;term PPI therapy and the development of fundic gland polyps is well described and these are recognized as the most frequent gastric mucosal lesions associated with PPI use. In a prospective study including 1,780 patients from Argentina, 4.3% had fundic gland polyps; 64% of patients with fundic gland polyps were on PPI therapy.<xref rid="deo2400-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> A meta&#x02010;analysis including 12 studies reported that the duration of PPI therapy is proportionate to the prevalence of fundic gland polyps.<xref rid="deo2400-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Jalving et&#x000a0;al. also reported that PPI administration for &#x0003e;5 years increases the prevalence of fundic gland polyps; cystic changes in these polyps were more prevalent in PPI users.<xref rid="deo2400-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="deo2400-fig-0001"><label>FIGURE 1</label><caption><p>Six representative gastric mucosal changes associated with vonoprazan/proton pump inhibitors: (a) fundic gland polyp, (b) gastric hyperplastic polyp, (c) multiple white and flat elevated lesions, (d) cobblestone&#x02010;like gastric mucosal changes, (e) gastric black spots (arrows), and (f) stardust gastric mucosal changes.</p></caption><graphic xlink:href="DEO2-5-e400-g001" position="anchor" id="jats-graphic-1"/></fig><p>The histological hallmark of fundic gland polyps associated with acid blocker use is cystic gland dilation due to parietal cell protrusion and foveolar cell proliferation.<xref rid="deo2400-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The underlying etiological pathway of this association with acid blockade is as yet unclear, but protrusion and hyperplasia of parietal cells are always present and are considered to be the precursor of these changes.<xref rid="deo2400-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Parietal cell protrusion (swelling and bulging of parietal cells) within the neck of fundic glands causes narrowing of secretory canaliculi, which may in turn cause retention of hydrochloric acid, resulting in the formation of fundic gland cysts.<xref rid="deo2400-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> The elevated intraglandular pressure caused by increased resistance to outflow enlarges fundic gland cysts and develops within the first month of PPI therapy.<xref rid="deo2400-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</p><p>A Japanese prospective study reported that the developmental rate of fundic gland polyps after starting PPI was 6.3% and 13.6% at 1 and 2 years, respectively; however, this study included a large population of <italic toggle="yes">H. pylori</italic>&#x02010;positive subjects (41%).<xref rid="deo2400-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Ongoing <italic toggle="yes">H. pylori</italic> infection reduces the prevalence of fundic gland polyps. We evaluated the prevalence of fundic gland polyps in patients treated with VPZ or PPI,<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="deo2400-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> and found these to be significantly more prevalent than in our control group (<italic toggle="yes">p</italic> &#x0003c; 0.001). Furthermore, the prevalence was significantly higher in the PPI group than in the VPZ group (<italic toggle="yes">p</italic> = 0.008). The prevalence of fundic gland polyps &#x0003e;10 mm in size was also significantly higher in the PPI group as compared with the VPZ and the control groups.<xref rid="deo2400-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> The results of the VISION study supported our aforementioned results and showed that the prevalence of fundic gland polyps in the PPI group was higher than in the VPZ group.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> As expected, considering its more potent acid suppression, serum gastrin levels are higher with VPZ as compared with PPI therapy. Although a correlation between fundic gland polyp formation and PPI use is well documented, it does not appear to be influenced by the associated hypergastrinemia. Two Japanese studies reported that there was no significant relationship between serum gastrin level and fundic gland polyp formation.<xref rid="deo2400-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="deo2400-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> This is echoed by the findings of another European study.<xref rid="deo2400-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Therefore, we hypothesize that fundic gland polyp formation associated with VPZ/PPI is influenced by a gastrin&#x02010;independent pathway.</p><p>PPI therapy increases parietal cell proliferation via elevated expression of aquaporin&#x02010;4.<xref rid="deo2400-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> In a mouse model, lansoprazole administration has been associated with histological findings similar to those of the fundic gland polyp, including multiple cystic dilatations and an increase in the number of water channel, aquaporin&#x02010;4 and potassium channel, KCNQ1&#x02010;positive parietal cells.<xref rid="deo2400-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> The function of aquaporins is to work as channels to transport water across cell membranes, in response to osmotic gradients.<xref rid="deo2400-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> A hemorrhagic fundic gland polyp associated with long&#x02010;term PPI administration was found to have aquaporin&#x02010;4 and KCNQ1&#x02010;positive parietal cells.<xref rid="deo2400-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> The aquaporin&#x02010;4 positive parietal cells increased by PPI therapy enhance water transport into parietal cells, resulting in an enhanced influx of water from the interstitial space into the oxyntic glands.<xref rid="deo2400-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Distribution of aquaporin&#x02010;4 and KCNQ1 during acid suppression therapy may explain the difference in the prevalence of fundic gland polyps between VPZ and PPI groups.</p><p>Although excessive enlargement of fundic gland polyps may cause bleeding, an increased number of fundic gland polyps is not considered to be of clinical concern, since their malignant potential is reported to be negligible.<xref rid="deo2400-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> It is not mandatory to cease acid blocker therapy due to the formation and/or increase of fundic gland polyps unless they cause bleeding or show signs of dysplasia. The subject merits further study.</p></sec><sec id="deo2400-sec-0040"><title>Gastric hyperplastic polyps</title><p>Gastric hyperplastic polyps are usually reddish and sessile and tend to form within the corpus and antrum (Figure&#x000a0;<xref rid="deo2400-fig-0001" ref-type="fig">1b</xref>); they may be associated with atrophic gastritis caused by persistent <italic toggle="yes">H. pylori</italic> infection.<xref rid="deo2400-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Their histopathology is characterized by excessive proliferation of the foveolar epithelium caused by chronic inflammation of the gastric mucosa. Successful eradication of <italic toggle="yes">H. pylori</italic> results in complete regression of gastric hyperplastic polyps in approximately 44%&#x02013;80% of patients.<xref rid="deo2400-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="deo2400-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="deo2400-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Growth of these lesions may result in spontaneous bleeding and malignant transformation.</p><p>Long&#x02010;term PPI administration is also associated with the development of gastric hyperplastic polyps. A Japanese prospective study and the VISION study found a similar prevalence of gastric hyperplastic polyps at 2 years of administration of PPIs (8.9% and 11.3%, respectively).<xref rid="deo2400-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> At 5 years follow&#x02010;up, the VISION study showed that the prevalence of these lesions in the VPZ group was higher than that of the PPI group (23% vs. 11%).<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> We previously reported a prevalence of biopsy&#x02010;proven gastric hyperplastic polyps in our VPZ and PPI groups (8% and 12%, respectively), the prevalence in both these groups was significantly higher than that of the control group (1%).<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Multivariate analysis showed that the presence of gastric hyperplastic polyp was significantly associated with both VPZ and PPI use.<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p><p>A Japanese study reported a positive correlation between the development of gastric hyperplastic polyps and serum gastrin levels.<xref rid="deo2400-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> However, these findings were confounded by the inclusion of a high percentage of <italic toggle="yes">H. pylori</italic>&#x02010;positive subjects (41%).<xref rid="deo2400-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Although immunohistochemical staining of PPI&#x02010;associated gastric hyperplastic polyps shows expression of gastrin receptors in the focal foveolar epithelium,<xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> the exact causal relationship between hypergastrinemia and the development of gastric hyperplastic polyps remains unclear.</p><p>Malignant transformation of gastric hyperplastic polyps remains a concern during VPZ/PPI therapy. Ahn et&#x000a0;al. showed that dysplasia/carcinoma was present in 3.7% of excised gastric hyperplastic polyps &#x0003e;1cm in size; loss of p16 expression and high Ki&#x02010;67 expression were observed in dysplastic areas of these lesions.<xref rid="deo2400-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> However, this study was again confounded by the inclusion of a percentage of patients with ongoing <italic toggle="yes">H. pylori</italic> infection (61%); furthermore, the proportion of patients on PPI therapy was not reported. Therefore, carcinogenesis may be influenced by <italic toggle="yes">H. pylori</italic>&#x02010;related inflammation rather than acid blockade. Hizawa et&#x000a0;al. also reported that 3.4% of resected gastric hyperplastic polyps had neoplastic components.<xref rid="deo2400-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> Immunohistochemical analyses of six gastric hyperplastic polyps (1&#x02013;4 cm in size) with malignant transformation indicated multistep carcinogenesis such as hyperplasia&#x02010;adenoma (dysplasia)&#x02010;adenocarcinoma sequence.<xref rid="deo2400-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Given the confounding factors of these studies, to date, there is no rigorous evidence to support malignant change in gastric hyperplastic polyps associated with VPZ/PPI use.</p><p>In order to assess for neoplastic transformation in gastric hyperplastic polyps, complete excision is advised, since biopsies alone are insufficient to exclude malignant change, as this may be limited to a tiny area of the lesion. PPI&#x02010;induced gastric hyperplastic polyps usually regress after cessation of PPI therapy.<xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="deo2400-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="deo2400-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref> If gastric hyperplastic polyps &#x0003c;1 cm developed during VPZ/PPI therapy, cessation of VPZ/PPI is not mandatory. However, gastric hyperplastic polyps &#x0003e;1 cm should be endoscopically resected when they do not regress even with cessation of VPZ/PPI.</p></sec><sec id="deo2400-sec-0050"><title>Multiple white and flat elevated lesions</title><p>Multiple white and flat elevated mucosal lesions spreading from the fundus to the corpus were first reported by Kawaguchi et&#x000a0;al. in 2007.<xref rid="deo2400-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Endoscopic findings are well&#x02010;circumscribed, round, slightly elevated, multiple lesions with smooth surfaces accompanied by white tubular structures (Figure&#x000a0;<xref rid="deo2400-fig-0001" ref-type="fig">1c</xref>). Linked color imaging, one of the image&#x02010;enhanced endoscopic optical modalities developed by Fujifilm Medical facilitates visualization of these lesions. Their histopathology is characterized by foveolar epithelial hyperplasia accompanied by parietal cell protrusions and fundic gland dilatations.<xref rid="deo2400-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="deo2400-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> In 2018, Hasegawa et&#x000a0;al. reported that multiple white and flat elevated lesions were associated with PPI use.<xref rid="deo2400-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> However, multivariate analysis in another Japanese study including 1995 subjects showed a significant association with female gender, advanced age, and moderate to severe gastric atrophy, but not with acid blocker use.<xref rid="deo2400-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Majima et&#x000a0;al. reported the prevalence of multiple white and flat elevated lesions as 10.4% and multivariate analysis identified advanced age, female gender, and PPI use as positive significant predictors.<xref rid="deo2400-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> In another, recent Japanese study published in 2023, the multivariate analysis identified PPI use as the only significant factor for these lesions.<xref rid="deo2400-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
</p><p>The VISION study showed slightly higher prevalence in the PPI group than in the VPZ group at 5 years after starting acid suppression therapy (14.9% vs. 8.9%).<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> This study did not include patients with a history of <italic toggle="yes">H. pylori</italic> eradication therapy, and therefore we may assume that patients with severe gastric atrophy were mostly excluded. We previously also reported on the prevalence of multiple white and flat elevated lesions. Our PPI group had a significantly higher prevalence as compared with the VPZ group (40% vs. 30%, <italic toggle="yes">p</italic> = 0.027); multivariate analysis identified advanced age, female gender, PPI use, and VPZ use as positive predictors.<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</p><p>Although there is a difference in prevalence rates of multiple white and flat elevated lesions among studies, it may be explained by the difference in the use of image&#x02010;enhanced endoscopies such as linked color imaging, blue laser imaging (BLI; Fujifilm Medical) and narrow&#x02010;band imaging (NBI, Olympus Medical) and/or the duration of VPZ/PPI use. Two Japanese studies including the VISION study and our retrospective study showed a similar tendency for PPI users to have more multiple white and flat elevated lesions than VPZ users.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> VPZ users had significantly stronger acid suppression and higher serum gastrin levels as compared with PPI users.<xref rid="deo2400-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> Multiple white and flat elevated lesions are frequently observed in patients with successful <italic toggle="yes">H. pylori</italic> eradication and possibly decreased serum gastrin levels.<xref rid="deo2400-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> A Japanese study did not show a significant difference between serum gastrin levels and these lesions.<xref rid="deo2400-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> We may therefore surmise that serum gastrin levels may not influence the development of these lesions. The malignant potential of multiple white and flat elevated lesions may be negligible.<xref rid="deo2400-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Even if multiple white and flat elevated lesions develop during VPZ/PPI therapy, cessation of clinically appropriate VPZ/PPI use is not necessary.</p></sec><sec id="deo2400-sec-0060"><title>Cobblestone&#x02010;like gastric mucosal changes</title><p>Cobblestone&#x02010;like mucosal changes are characterized by innumerable, slightly elevated lesions that are &#x0003c;5 mm in size; it is also known as &#x02018;cracked gastric mucosa&#x02019; (Figure&#x000a0;<xref rid="deo2400-fig-0001" ref-type="fig">1d</xref>).<xref rid="deo2400-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> The histopathological findings are those of oxyntic gland dilation, cytoplasmic vacuolation, and parietal cell protrusion.<xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="deo2400-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="deo2400-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> The visualized mucosal elevation may be caused by this oxyntic gland dilation.</p><p>A Japanese study reported the prevalence of cobblestone&#x02010;like gastric mucosal changes to be 3.4%, with the multivariate analysis identifying diabetes mellitus and PPI use as significant associated factors; treatment duration of PPI was not correlated with prevalence.<xref rid="deo2400-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> Another Japanese study confirmed these findings, and showed a significantly higher prevalence of cobblestone&#x02010;like mucosal changes in PPI users as compared with patients who were not on PPI therapy (24.4% vs. 3.7%, <italic toggle="yes">p</italic> &#x0003c; 0.01); treatment duration was also not found to be an independent predictor.<xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Interestingly, none of the patients with cobblestone&#x02010;like mucosal changes had active <italic toggle="yes">H. pylori</italic> infection, and most of these did not have any gastric atrophy.<xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> In the cohort of 171 patients who had been treated with PPIs for &#x0003e; six months, 35% were found to have cobblestone&#x02010;like mucosal changes.<xref rid="deo2400-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref> Cobblestone&#x02010;like mucosal change was also found to be more frequent in dialysis patients with associated hypergastrinemia<xref rid="deo2400-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>; however, elevated gastrin levels in dialysis patients is mainly caused by &#x02018;big gastrin&#x02019; (G&#x02010;34), which has a much weaker function than &#x02018;little gastrin&#x02019; (G&#x02010;17).<xref rid="deo2400-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> Patients with cobblestone&#x02010;like gastric mucosal changes tend to lack gastric mucosal atrophy. While the serum gastrin level is proportionate to the degree of gastric atrophy,<xref rid="deo2400-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="deo2400-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> the precise mechanism of the development of a cobblestone&#x02010;like mucosal change is unclear. Although the association of cobblestone&#x02010;like mucosal changes with hypergastrinemia is worthy of attention, two studies did not show a direct correlation with its presence.<xref rid="deo2400-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="deo2400-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Therefore, as yet unknown, alternative causative pathway, is more likely to be at play.</p><p>The presence of cobblestone&#x02010;like mucosal changes in patients treated with VPZ was first reported by Miyamoto et&#x000a0;al.<xref rid="deo2400-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> At 5&#x02010;year follow&#x02010;up, the VISION study also reported its presence in 22.1% and 15.1% in the VPZ and PPI groups, respectively.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In our previous study,<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> the prevalence in the VPZ and PPI groups was 9% and 12%, respectively, and these rates were significantly higher than that of the control group (0.6%).<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Multivariate analysis identified male gender, VPZ, and PPI use as significant associated factors.<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Further studies are necessary to understand the development of cobblestone&#x02010;like mucosal changes, its association with the acid blockade, and any clinical significance.</p></sec><sec id="deo2400-sec-0070"><title>Gastric black spots</title><p>This comparatively rare lesion was first reported in 2016 by Hatano et&#x000a0;al.<xref rid="deo2400-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> It is more likely to occur in patients with long&#x02010;term PPI treatment who have been on the drug for more than 1 year. The prevalence was reported as 0.24% in routine esophagogastroduodenoscopy, and all black spots were located on the fundic gland region (Figure&#x000a0;<xref rid="deo2400-fig-0001" ref-type="fig">1e</xref>). Black spots are present on fundic gland polyps or the flat mucosa, and they are histologically characterized by parietal cell protrusions, fundic gland cysts, and brownish pigmentation in the fundic gland cysts resulting from the accumulation of mucus. Therefore, gastric black spots are also considered to be a gastric mucosal change associated with PPI use.</p><p>In contrast to the aforementioned study,<xref rid="deo2400-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> Adachi et&#x000a0;al. reported a higher prevalence of gastric black spots, of the order of 9.8% (156/1600).<xref rid="deo2400-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> This study identified advanced age and a history of <italic toggle="yes">H. pylori</italic> eradication as significant associated factors, but not PPI use. Of these patients with black spots, 92% had a history of <italic toggle="yes">H. pylori</italic> eradication.<xref rid="deo2400-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> Another Japanese study including 1214 patients reported the prevalence of black spots to be 6.2%; multivariate analysis identified low body mass index, a history of <italic toggle="yes">H. pylori</italic> eradication and PPI use as significant factors.<xref rid="deo2400-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> Therefore, the presence of black spots may be considered a hallmark of successful <italic toggle="yes">H. pylori</italic> eradication. The VISION study found the prevalence of black spots in VPZ and PPI users at 5&#x02010;year follow&#x02010;up to be 7.7% and 13.2%, respectively.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>The precise mechanism for the development and prevalence of black spots remains elusive, and its association with VPZ/PPI use is also unclear. Although association with hypergastrinemia was reported,<xref rid="deo2400-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> the VISION study<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> did not support this association, since black spots were found more frequently in PPI users than in VPZ users. It is therefore likely that hypergastrinemia may have little influence on the development of gastric black spots. Further larger studies are warranted to clarify the association of VPZ/PPI therapy and any clinical relevance of gastric black spots.</p></sec><sec id="deo2400-sec-0080"><title>Stardust gastric mucosal changes</title><p>The detailed endoscopic and pathological images of stardust gastric mucosal lesions were first reported as &#x0201c;white globe appearance&#x0201d; that contains intraglandular necrotic debris.<xref rid="deo2400-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="deo2400-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> After the release of VPZ, the presence of multiple small white protrusions, located within the fundus and corpus as observed at esophagogastroduodenoscopy was reported in 2020 by Yoshizaki et&#x000a0;al.<xref rid="deo2400-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> Due to its appearance, this was termed &#x02018;stardust gastric mucosa&#x02019; (Figure&#x000a0;<xref rid="deo2400-fig-0001" ref-type="fig">1f</xref>). The prevalence rates in VPZ and non&#x02010;VPZ users were 4.9% and 0.2%, respectively. The histopathological features are of a mucus pool within a dilated duct surrounded by flattened glandular epithelium, accompanied by parietal cell protrusion/vacuolation.<xref rid="deo2400-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="deo2400-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> In multivariate analysis, the risk factors were found to be female gender and long&#x02010;term VPZ use. Both the prevalence rate and the number of lesions were proportionate to the duration of VPZ therapy.<xref rid="deo2400-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</p><p>In 2021, Nishiyama et&#x000a0;al. termed the stardust gastric mucosal changes as &#x0201c;white spots&#x0201d;.<xref rid="deo2400-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="deo2400-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> There was a higher prevalence in the group of patients on acid blockade therapy than that of the control group (27.5% vs. 1.3%, respectively, <italic toggle="yes">p</italic> &#x0003c; 0.001). The VPZ group showed a significantly higher prevalence than the PPI group (68% vs. 12%, <italic toggle="yes">p</italic> &#x0003c; 0.001). The serum gastrin level was significantly higher in patients with stardust gastric mucosal changes than in those without this finding. In VPZ users, patients with stardust gastric mucosal changes had significantly higher serum gastrin levels than those without (<italic toggle="yes">p</italic> &#x0003c; 0.05). The multivariate analysis identified high serum gastrin level and VPZ use as associated factors.</p><p>In 2022, we reported on the prevalence of stardust gastric mucosal changes.<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> The prevalence was 48%, 11%, and 0.5% in the VPZ, PPI, and control groups, respectively. The prevalence in the VPZ and PPI groups was significantly higher than that of the control group (<italic toggle="yes">p</italic> &#x0003c; 0.001); the VPZ group had a significantly higher prevalence than the PPI group. In multivariate analysis, both VPZ and PPI use were identified as positive significant factors associated with stardust gastric mucosal change. Female gender was also a significant associated factor. Therefore, stardust gastric mucosal change is not a specific lesion associated solely with VPZ therapy.</p><p>In the latter two studies, the prevalence rates were similar,<xref rid="deo2400-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="deo2400-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> and much higher than that of the first report.<xref rid="deo2400-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> We hypothesize that the reported difference in prevalence may be explained both by the duration of acid suppression therapy and the endoscopists&#x02019; subsequent heightened awareness of this finding. Although a correlation between hypergastrinemia and stardust gastric mucosal change was reported, a causal relationship is not evident. Although concerns were raised regarding the possible associated development of neuroendocrine neoplasia,<xref rid="deo2400-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> these are allayed by the fact that stardust gastric mucosal change is also observed in patients treated with PPIs, drugs that have been safely in us for over 30 years. Although there is no evident association with neoplastic change, further large studies are necessary to elucidate the mechanism of development of stardust gastric mucosal change and its long&#x02010;term natural history.</p></sec><sec id="deo2400-sec-0090"><title>Gastric atrophy</title><p>The presence of gastric atrophy has been definitively associated with an increased risk of gastric cancer.<xref rid="deo2400-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> Although a possible association between PPI use and gastric atrophy has been discussed, the pooled analysis including 1070 participants from four randomized&#x02010;controlled trials showed no statistically significant differences in risk between PPI users and non&#x02010;PPI users (odds ratio 1.50, 95% confidence interval 0.59&#x02013;3.80, <italic toggle="yes">p</italic> = 0.39).<xref rid="deo2400-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Long&#x02010;term PPI use is not associated with the development of intestinal metaplasia.<xref rid="deo2400-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> A recent randomized controlled trial with 3 years of follow&#x02010;up did not demonstrate a significant association between PPI use and gastric atrophy.<xref rid="deo2400-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> Perhaps surprisingly, the 3&#x02010;year interim analysis of the VISION study showed improvement in antral gastric atrophy in both the VPZ and PPI groups.<xref rid="deo2400-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> Therefore, we believe that the progression of gastric atrophy is mainly influenced by <italic toggle="yes">H. pylori</italic> infection status, rather than acid blockade.</p></sec><sec id="deo2400-sec-0100"><title>Hypergastrinemia</title><p>Gastrin, secreted by the G cells within the gastric antrum is an important hormone for modulation of gastric acid secretion through the regulation of ECL cell function. The hypoacidity caused by acid suppression therapy stimulates gastrin secretion through negative feedback, and this results in ECL cell hyperplasia. In animal models, ECL cell density has been found to be proportionate to the serum gastrin level, and efficient inhibition of gastric acid secretion is accomplished through its maximal trophic effect.<xref rid="deo2400-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> In humans, hypergastrinemia also induces a trophic effect on the oxyntic mucosa and ECL cells.<xref rid="deo2400-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> However, concern about long&#x02010;term acid suppression therapy with VPZ/PPI, has led to a focus on serum gastrin level measurement, regardless of the unknown clinical significance of its elevation in the context of long&#x02010;term acid blockade therapy.</p><p>A Japanese study including 382 patients reported that PPI use, corpus atrophy, and female gender were identified as positive significant factors for hypergastrinemia in multivariate analysis.<xref rid="deo2400-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> In the VISION study, the serum gastrin level of the PPI and VPZ groups during the 5&#x02010;year treatment period ranged approximately from 300&#x02013;400 to 700&#x02013;900 pg/mL, respectively, and the values were significantly higher than the baseline (approx. 130&#x02013;150).<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> However, the proportion of patients with ECL&#x02010;cell hyperplasia was similar between VPZ and PPI groups at 5 years of follow&#x02010;up (VPZ 4.9% vs. PPI 7.7%, respectively).<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</p><p>In our retrospective study excluding patients with current <italic toggle="yes">H. pylori</italic> infection published in 2022, we reported the 4&#x02010;year changes in serum gastrin level in patients continuously treated with VPZ.<xref rid="deo2400-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> Overall, the serum gastrin level for 4 years was in the range of 700&#x02013;1200 pg/mL; this plateaued at 1.5 years and was maintained for 2.5 years without further elevation.<xref rid="deo2400-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> This long&#x02010;term change was similar to the findings of a previous study of patients on PPI therapy, where serum gastrin level plateaued at about 1&#x02013;2 years and was maintained for 3&#x02013;4 years.<xref rid="deo2400-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> In our VPZ study, multivariate analysis revealed that severe gastric atrophy was associated with hypergastrinemia. The gastrin level over 4 years in patients with severe gastric atrophy and those with no atrophy was in the range of 900&#x02013;1500 and 500&#x02013;1000 pg/mL, respectively.<xref rid="deo2400-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref> The latter value was similar to the serum gastrin value observed in the VISION study which mostly included patients without gastric atrophy.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In a multicenter prospective study, the VPZ group showed significantly higher serum gastrin levels than the PPI group, in patients with no or mild gastric atrophy.<xref rid="deo2400-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> However, no significant difference between both groups was observed in patients with severe gastric atrophy.</p><p>The clinical significance of long&#x02010;term hypergastrinemia caused by acid blockers is still unclear, and serum gastrin level can be influenced by multiple factors including gastric atrophy, chronic kidney disease, glucocorticoid therapy, as well as VPZ/PPI use.<xref rid="deo2400-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> In a recent study evaluating the human gastric mucosa, no relationship was found between neuroendocrine markers and hypergastrinemia secondary to long&#x02010;term PPI therapy.<xref rid="deo2400-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref> An increase in serum gastrin level alone is therefore not considered to be a valid reason for the cessation of clinically appropriate long&#x02010;term VPZ/PPI therapy. Periodical measurement of serum gastrin levels is discouraged since it is neither necessary nor helpful for decision&#x02010;making in routine clinical practice.</p></sec><sec id="deo2400-sec-0110"><title>Gastric neuroendocrine neoplasm</title><p>The potential development of neuroendocrine tumors during acid suppression therapy has always been of concern. The development of such tumors requires multistep carcinogenesis commencing at ECL cell hyperplasia. A systematic review showed that ECL cell hyperplasia is significantly associated with PPI use.<xref rid="deo2400-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> However, there is no rigorous evidence to suggest that VPZ/PPI administration increases the risk of gastric neuroendocrine tumor development; this is supported by the Japanese Guidelines.<xref rid="deo2400-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Since VPZ users have significantly higher serum gastrin levels as compared with PPI users,<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> the potential development of neuroendocrine neoplasm via ECL cell hyperplasia during VPZ remained of concern. The VISION study evaluated gastric biopsies at 5 years of follow&#x02010;up since the start of VPZ/PPI therapy and reassuringly showed a similar rate of ECL cell hyperplasia (1&#x02010;6%) without the development of neuroendocrine tumors.<xref rid="deo2400-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Although there are anecdotal reports indicating neuroendocrine tumor development during VPZ therapy,<xref rid="deo2400-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> there are no studies demonstrating a significant relationship between VPZ use and neuroendocrine tumor formation.</p><p>
<italic toggle="yes">H. pylori</italic> eradication success can decrease serum gastrin levels and is therefore strongly recommended before commencing VPZ/PPI therapy. If the development of a neuroendocrine tumor is confirmed, VPZ/PPI treatment should be discontinued. VPZ/PPI administration should be avoided in patients with type A gastritis because of its associated strong hypergastrinemia and high risk of neuroendocrine tumor formation. A Japanese multicenter retrospective study reported a favorable prognosis in patients with type 1 gastric carcinoids during long&#x02010;term follow&#x02010;up (disease&#x02010;specific survival: 100%).<xref rid="deo2400-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Even if type 1 gastric neuroendocrine tumors develop, their presence will not influence overall survival as long as these are appropriately managed. Nevertheless, we cannot eliminate the relationship between acid blockade and the development of gastric neuroendocrine tumors. Since carcinogenesis (as is also seen in the case of <italic toggle="yes">H. pylori</italic>) may take several decades to develop, long&#x02010;term observation for more than 10 years is necessary to fully understand any potential associated risk for the development of gastric malignancy. The present evidence is therefore still not sufficient to rule out any potential risk of malignancy associated with long&#x02010;term administration of VPZ/PPI.</p></sec></sec><sec id="deo2400-sec-0120"><title>CONCLUSION</title><p>The risk of gastric mucosal change is similar for long&#x02010;term VPZ and PPI use. Hypergastrinemia is not correlated with the development of fundic gland polyps, gastric black spots, and multiple white and flat elevated lesions. Therefore, serum gastrin level is unhelpful in routine clinical practice and cannot serve as a guide for the cessation of VPZ/PPI therapy. To avoid a confounding factor that is intrinsically associated with malignant risk, patients with <italic toggle="yes">H. pylori</italic> infection should be excluded from future studies on this subject. It is also essential to ensure that <italic toggle="yes">H. pylori</italic> eradication is successfully achieved before the commencement of VPZ/PPI therapy. The development of the aforementioned gastric mucosal lesions alone during VPZ/PPI therapy is not considered a justified reason for the cessation of clinically appropriate VPZ/PPI therapy. Although such mucosal changes during long&#x02010;term use of VPZ/PPI should be observed, the benefits of clinically appropriate acid blockade presently outweigh any currently understood risks. However, the matter merits further longitudinal, follow&#x02010;up studies to confirm the long&#x02010;term safety of prolonged therapy with these agents.</p></sec><sec sec-type="COI-statement" id="deo2400-sec-0130"><title>CONFLICT OF INTEREST STATEMENT</title><p>Satoshi Shinozaki, Hiroyuki Osawa, and Yoshimasa Miura have received honoraria from Takeda and Otsuka Pharmaceuticals. Hirotsugu Sakamoto, Tomonori Yano, and Hironori Yamamoto have received honoraria from Takeda Pharmaceutical. All other authors declare no conflict of interest.</p></sec><sec id="deo2400-sec-0140"><title>ETHICS STATEMENT</title><p>Not applicable.</p></sec></body><back><ref-list id="deo2400-bibl-0001"><title>REFERENCES</title><ref id="deo2400-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo2400-cit-0001">
<string-name>
<surname>Rotman</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Bishop</surname>
<given-names>TF</given-names>
</string-name>. <article-title>Proton pump inhibitor use in the U.S. ambulatory setting, 2002&#x02013;2009</article-title>. <source>PLoS One</source>
<year>2013</year>; <volume>8</volume>: <elocation-id>e56060</elocation-id>.<pub-id pub-id-type="pmid">23418510</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo2400-cit-0002">
<string-name>
<surname>Lanas</surname>
<given-names>A</given-names>
</string-name>. <article-title>We are using too many PPIs, and we need to stop: A European perspective</article-title>. <source>Am J Gastroenterol</source>
<year>2016</year>; <volume>111</volume>: <fpage>1085</fpage>&#x02013;<lpage>1086</lpage>.<pub-id pub-id-type="pmid">27166129</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo2400-cit-0003">
<string-name>
<surname>Kamada</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Time trends in <italic toggle="yes">Helicobacter pylori</italic> infection and atrophic gastritis over 40 years in Japan</article-title>. <source>Helicobacter</source>
<year>2015</year>; <volume>20</volume>: <fpage>192</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">25581708</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo2400-cit-0004">
<string-name>
<surname>Osawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kita</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ohnishi</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Helicobacter pylori eradication induces marked increase in H+/K+&#x02010;adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa</article-title>. <source>Gut</source>
<year>2006</year>; <volume>55</volume>: <fpage>152</fpage>&#x02013;<lpage>157</lpage>.<pub-id pub-id-type="pmid">15872000</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo2400-cit-0005">
<string-name>
<surname>Adachi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Katsube</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kawamura</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2000</year>; <volume>14</volume>: <fpage>1259</fpage>&#x02013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">11012469</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo2400-cit-0006">
<string-name>
<surname>Peghini</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Katz</surname>
<given-names>PO</given-names>
</string-name>, <string-name>
<surname>Bracy</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Castell</surname>
<given-names>DO</given-names>
</string-name>. <article-title>Nocturnal recovery of gastric acid secretion with twice&#x02010;daily dosing of proton pump inhibitors</article-title>. <source>Am J Gastroenterol</source>
<year>1998</year>; <volume>93</volume>: <fpage>763</fpage>&#x02013;<lpage>767</lpage>.<pub-id pub-id-type="pmid">9625124</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo2400-cit-0007">
<string-name>
<surname>Sakurai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mori</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Acid&#x02010;inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects&#x02013;A randomised open&#x02010;label cross&#x02010;over study</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2015</year>; <volume>42</volume>: <fpage>719</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">26193978</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo2400-cit-0008">
<string-name>
<surname>Kagami</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sahara</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ichikawa</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2016</year>; <volume>43</volume>: <fpage>1048</fpage>&#x02013;<lpage>1059</lpage>.<pub-id pub-id-type="pmid">26991399</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo2400-cit-0009">
<string-name>
<surname>Matsukawa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hori</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nishida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kajino</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inatomi</surname>
<given-names>N</given-names>
</string-name>. <article-title>A comparative study on the modes of action of TAK&#x02010;438, a novel potassium&#x02010;competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands</article-title>. <source>Biochem Pharmacol</source>
<year>2011</year>; <volume>81</volume>: <fpage>1145</fpage>&#x02013;<lpage>1151</lpage>.<pub-id pub-id-type="pmid">21371447</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo2400-cit-0010">
<string-name>
<surname>Hori</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Matsukawa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Nishida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kajino</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inatomi</surname>
<given-names>N</given-names>
</string-name>. <article-title>A study comparing the antisecretory effect of TAK&#x02010;438, a novel potassium&#x02010;competitive acid blocker, with lansoprazole in animals</article-title>. <source>J Pharmacol Exp Ther</source>
<year>2011</year>; <volume>337</volume>: <fpage>797</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">21411494</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo2400-cit-0011">
<string-name>
<surname>Shinozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lefor</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>H</given-names>
</string-name>. <article-title>Long&#x02010;term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor&#x02010;resistant gastroesophageal reflux disease</article-title>. <source>Biomed Rep</source>
<year>2021</year>; <volume>14</volume>: <fpage>32</fpage>.<pub-id pub-id-type="pmid">33585034</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo2400-cit-0012">
<string-name>
<surname>Shinozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Long&#x02010;term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan</article-title>. <source>Scand J Gastroenterol</source>
<year>2018</year>; <volume>53</volume>: <fpage>897</fpage>&#x02013;<lpage>904</lpage>.<pub-id pub-id-type="pmid">30056768</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo2400-cit-0013">
<string-name>
<surname>Ashida</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sakurai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Hori</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Randomised clinical trial: Vonoprazan, a novel potassium&#x02010;competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2016</year>; <volume>43</volume>: <fpage>240</fpage>&#x02013;<lpage>251</lpage>.<pub-id pub-id-type="pmid">26559637</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo2400-cit-0014">
<string-name>
<surname>Zou</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ouyang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>M</given-names>
</string-name>. <article-title>Acid&#x02010;suppressive drugs: A systematic review and network meta&#x02010;analysis of their nocturnal acid&#x02010;inhibitory effect</article-title>. <source>Pharmacotherapy</source>
<year>2024</year>; <volume>44</volume>: <fpage>171</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">38049205</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo2400-cit-0015">
<string-name>
<surname>Uemura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kushima</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kanoo</surname>
<given-names>T</given-names>
</string-name>. <article-title>Rationale and design of the VISION study: A randomized, open&#x02010;label study to evaluate the long&#x02010;term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis</article-title>. <source>Clin Exp Gastroenterol</source>
<year>2018</year>; <volume>11</volume>: <fpage>51</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">29416369</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo2400-cit-0016">
<string-name>
<surname>Kim</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Seo</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Kang</surname>
<given-names>SH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: A multicenter double&#x02010;blind randomized controlled trial</article-title>. <source>J Neurogastroenterol Motil</source>
<year>2023</year>; <volume>29</volume>: <fpage>58</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">36581325</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo2400-cit-0017">
<string-name>
<surname>Kim</surname>
<given-names>GH</given-names>
</string-name>. <article-title>Proton pump inhibitor&#x02010;related gastric mucosal changes</article-title>. <source>Gut Liver</source>
<year>2021</year>; <volume>15</volume>: <fpage>646</fpage>&#x02013;<lpage>652</lpage>.<pub-id pub-id-type="pmid">32327613</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo2400-cit-0018">
<string-name>
<surname>Song</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>D</given-names>
</string-name>. <article-title>Long&#x02010;term proton pump inhibitor (PPI) use and the development of gastric pre&#x02010;malignant lesions</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2014</year>; <volume>2014</volume>: <elocation-id>CD010623</elocation-id>.<pub-id pub-id-type="pmid">25464111</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo2400-cit-0019">
<string-name>
<surname>Driman</surname>
<given-names>DK</given-names>
</string-name>, <string-name>
<surname>Wright</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tougas</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Riddell</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Omeprazole produces parietal cell hypertrophy and hyperplasia in humans</article-title>. <source>Dig Dis Sci</source>
<year>1996</year>; <volume>41</volume>: <fpage>2039</fpage>&#x02013;<lpage>2047</lpage>.<pub-id pub-id-type="pmid">8888719</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo2400-cit-0020">
<string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>EP54 Final observation results of vision trial: A randomized, open&#x02010;label study to evaluate the long&#x02010;term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis</article-title>. <source>Gastroenterology</source>
<year>2023</year>; <volume>164</volume> (S&#x02010;1202).</mixed-citation></ref><ref id="deo2400-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo2400-cit-0021">
<string-name>
<surname>Carmack</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Genta</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Schuler</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Saboorian</surname>
<given-names>MH</given-names>
</string-name>. <article-title>The current spectrum of gastric polyps: A 1&#x02010;year national study of over 120,000 patients</article-title>. <source>Am J Gastroenterol</source>
<year>2009</year>; <volume>104</volume>: <fpage>1524</fpage>&#x02013;<lpage>1532</lpage>.<pub-id pub-id-type="pmid">19491866</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo2400-cit-0022">
<string-name>
<surname>Zelter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Bilder</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Fundic gland polyps and association with proton pump inhibitor intake: A prospective study in 1,780 endoscopies</article-title>. <source>Dig Dis Sci</source>
<year>2011</year>; <volume>56</volume>: <fpage>1743</fpage>&#x02013;<lpage>1748</lpage>.<pub-id pub-id-type="pmid">21127978</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo2400-cit-0023">
<string-name>
<surname>Martin</surname>
<given-names>FC</given-names>
</string-name>, <string-name>
<surname>Chenevix&#x02010;Trench</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Yeomans</surname>
<given-names>ND</given-names>
</string-name>. <article-title>Systematic review with meta&#x02010;analysis: Fundic gland polyps and proton pump inhibitors</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2016</year>; <volume>44</volume>: <fpage>915</fpage>&#x02013;<lpage>925</lpage>.<pub-id pub-id-type="pmid">27634363</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo2400-cit-0024">
<string-name>
<surname>Jalving</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Koornstra</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Wesseling</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Boezen</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<given-names>S</given-names>
<surname>DEJ</surname>
</string-name>, <string-name>
<surname>Kleibeuker</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Increased risk of fundic gland polyps during long&#x02010;term proton pump inhibitor therapy</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2006</year>; <volume>24</volume>: <fpage>1341</fpage>&#x02013;<lpage>1348</lpage>.<pub-id pub-id-type="pmid">17059515</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo2400-cit-0025">
<string-name>
<surname>Fukuda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ishigaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sugimoto</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Histological analysis of fundic gland polyps secondary to PPI therapy</article-title>. <source>Histopathology</source>
<year>2019</year>; <volume>75</volume>: <fpage>537</fpage>&#x02013;<lpage>545</lpage>.<pub-id pub-id-type="pmid">31087669</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="deo2400-cit-0026">
<string-name>
<surname>Cats</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schenk</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Bloemena</surname>
<given-names>E</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment</article-title>. <source>Hum Pathol</source>
<year>2000</year>; <volume>31</volume>: <fpage>684</fpage>&#x02013;<lpage>690</lpage>.<pub-id pub-id-type="pmid">10872661</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo2400-cit-0027">
<string-name>
<surname>Hongo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fujimoto</surname>
<given-names>K</given-names>
</string-name>. <article-title>Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long&#x02010;term proton pump inhibitor therapy: A prospective study in Japan</article-title>. <source>J Gastroenterol</source>
<year>2010</year>; <volume>45</volume>: <fpage>618</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">20177714</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="deo2400-cit-0028">
<string-name>
<surname>Shinozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The effect of proton pump inhibitors and vonoprazan on the development of &#x02018;gastric mucosal redness&#x02019;</article-title>. <source>Biomed Rep</source>
<year>2022</year>; <volume>16</volume>: <fpage>51</fpage>.<pub-id pub-id-type="pmid">35620314</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="deo2400-cit-0029">
<string-name>
<surname>Shinozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Changes in gastric morphology during long&#x02010;term use of vonoprazan compared to proton pump inhibitors</article-title>. <source>Singapor Med J</source>
<year>2021</year>; <volume>63</volume>: <fpage>283</fpage>&#x02013;<lpage>287</lpage>.</mixed-citation></ref><ref id="deo2400-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="deo2400-cit-0030">
<string-name>
<surname>Nishiyama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kobara</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kagawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nishiyama</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Masaki</surname>
<given-names>T</given-names>
</string-name>. <article-title>Vonoprazan may cause white globe appearance in nonatrophic mucosa of stomach</article-title>. <source>Gastrointest Endosc</source>
<year>2021</year>; <volume>93</volume>: <fpage>767</fpage>&#x02013;<lpage>768</lpage>.<pub-id pub-id-type="pmid">32980367</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="deo2400-cit-0031">
<string-name>
<surname>Fossmark</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jianu</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Martinsen</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Qvigstad</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Syversen</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Waldum</surname>
<given-names>HL</given-names>
</string-name>. <article-title>Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long&#x02010;term proton&#x02010;pump inhibition</article-title>. <source>Scand J Gastroenterol</source>
<year>2008</year>; <volume>43</volume>: <fpage>20</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">18938772</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="deo2400-cit-0032">
<string-name>
<surname>Matsuzaki</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Minegishi</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Acid suppression by proton pump inhibitors enhances aquaporin&#x02010;4 and KCNQ1 expression in gastric fundic parietal cells in mouse</article-title>. <source>Dig Dis Sci</source>
<year>2010</year>; <volume>55</volume>: <fpage>3339</fpage>&#x02013;<lpage>3348</lpage>.<pub-id pub-id-type="pmid">20437101</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="deo2400-cit-0033">
<string-name>
<given-names>Verkman AS.</given-names>
</string-name>
<article-title>Aquaporins</article-title>. <source>Curr Biol</source>
<year>2013</year>; <volume>23</volume>: <fpage>R52</fpage>&#x02013;<lpage>R55</lpage>.<pub-id pub-id-type="pmid">23347934</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="deo2400-cit-0034">
<string-name>
<surname>Takeda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Asaoka</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Tajima</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Hemorrhagic polyps formed like fundic gland polyps during long&#x02010;term proton pump inhibitor administration</article-title>. <source>Clin J Gastroenterol</source>
<year>2017</year>; <volume>10</volume>: <fpage>478</fpage>&#x02013;<lpage>484</lpage>.<pub-id pub-id-type="pmid">28660530</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="deo2400-cit-0035">
<string-name>
<surname>Naruki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Fujino</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ohnuma</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Histopathologic and immunohistochemical characterization of human gastric oxyntic mucosa with parietal cell protrusions and investigation into the association between such mucosal changes of the stomach and use of proton pump inhibitors</article-title>. <source>J St Marianna Univ</source>
<year>2015</year>; <volume>6</volume>: <fpage>119</fpage>&#x02013;<lpage>130</lpage>.</mixed-citation></ref><ref id="deo2400-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="deo2400-cit-0036">
<string-name>
<surname>Elhanafi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Saadi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lou</surname>
<given-names>W</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric polyps: Association with <italic toggle="yes">Helicobacter pylori</italic> status and the pathology of the surrounding mucosa, a cross sectional study</article-title>. <source>World J Gastrointest Endosc</source>
<year>2015</year>; <volume>7</volume>: <fpage>995</fpage>&#x02013;<lpage>1002</lpage>.<pub-id pub-id-type="pmid">26265993</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="deo2400-cit-0037">
<string-name>
<surname>Ji</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>ZW</given-names>
</string-name>, <string-name>
<surname>Ning</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>QY</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>YM</given-names>
</string-name>. <article-title>Effect of drug treatment on hyperplastic gastric polyps infected with <italic toggle="yes">Helicobacter pylori</italic>: A randomized, controlled trial</article-title>. <source>World J Gastroenterol</source>
<year>2006</year>; <volume>12</volume>: <fpage>1770</fpage>&#x02013;<lpage>1773</lpage>.<pub-id pub-id-type="pmid">16586550</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="deo2400-cit-0038">
<string-name>
<surname>Ohkusa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Takashimizu</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Fujiki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Disappearance of hyperplastic polyps in the stomach after eradication of <italic toggle="yes">Helicobacter pylori</italic>. A randomized, clinical trial</article-title>. <source>Ann Intern Med</source>
<year>1998</year>; <volume>129</volume>: <fpage>712</fpage>&#x02013;<lpage>715</lpage>.<pub-id pub-id-type="pmid">9841603</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="deo2400-cit-0039">
<string-name>
<surname>Ljubici&#x00107;</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Bani&#x00107;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kujundzi&#x00107;</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The effect of eradicating <italic toggle="yes">Helicobacter pylori</italic> infection on the course of adenomatous and hyperplastic gastric polyps</article-title>. <source>Eur J Gastroenterol Hepatol</source>
<year>1999</year>; <volume>11</volume>: <fpage>727</fpage>&#x02013;<lpage>730</lpage>.<pub-id pub-id-type="pmid">10445791</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="deo2400-cit-0040">
<string-name>
<surname>Miyamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tsuda</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Gastric mucosal cracked and cobblestone&#x02010;like changes resulting from proton pump inhibitor use</article-title>. <source>Dig Endosc</source>
<year>2017</year>; <volume>29</volume>: <fpage>307</fpage>&#x02013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">27859804</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="deo2400-cit-0041">
<string-name>
<surname>Ahn</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Son</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>KD</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Neoplasms arising in large gastric hyperplastic polyps: Endoscopic and pathologic features</article-title>. <source>Gastrointest Endosc</source>
<year>2014</year>; <volume>80</volume>: <fpage>1005</fpage>&#x02013;<lpage>1013.e2</lpage>. <ext-link xlink:href="https://www.giejournal.org/article/S0016-5107(14)01356-X/abstract" ext-link-type="uri">https://www.giejournal.org/article/S0016-5107(14)01356&#x02010;X/abstract</ext-link>
<pub-id pub-id-type="pmid">24929480</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="deo2400-cit-0042">
<string-name>
<surname>Hizawa</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fuchigami</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Iida</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Possible neoplastic transformation within gastric hyperplastic polyp. Application of endoscopic polypectomy</article-title>. <source>Surg Endosc</source>
<year>1995</year>; <volume>9</volume>: <fpage>714</fpage>&#x02013;<lpage>718</lpage>.<pub-id pub-id-type="pmid">7482172</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="deo2400-cit-0043">
<string-name>
<surname>Imura</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ichikawa</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Malignant transformation of hyperplastic gastric polyps: An immunohistochemical and pathological study of the changes of neoplastic phenotype</article-title>. <source>Oncol Lett</source>
<year>2014</year>; <volume>7</volume>: <fpage>1459</fpage>&#x02013;<lpage>1463</lpage>.<pub-id pub-id-type="pmid">24765156</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="deo2400-cit-0044">
<string-name>
<surname>Parks</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ragland</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Steiner</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Subramony</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bishop</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nowicki</surname>
<given-names>M</given-names>
</string-name>. <article-title>M&#x000e9;n&#x000e9;trier Mimicker complicating ulcerative colitis: Proton&#x02010;pump inhibitor&#x02010;induced hyperplastic polyps</article-title>. <source>J Pediatr</source>
<year>2015</year>; <volume>167</volume>: <elocation-id>776e1</elocation-id>.</mixed-citation></ref><ref id="deo2400-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="deo2400-cit-0045">
<string-name>
<surname>Alqutub</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Masoodi</surname>
<given-names>I</given-names>
</string-name>. <article-title>A case of gastric polyposis in antral area of stomach following prolonged proton&#x02010;pump therapy</article-title>. <source>Ger Med Sci</source>
<year>2010</year>; <volume>8</volume>: <elocation-id>Doc19</elocation-id>.<pub-id pub-id-type="pmid">20930929</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="deo2400-cit-0046">
<string-name>
<surname>Kawaguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ara</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Nozawa</surname>
<given-names>H</given-names>
</string-name>. <article-title>An investigation of white flat elevations in the gastric body</article-title>. <source>Gastroenterol Endosc</source>
<year>2007</year>; <volume>49</volume>: <fpage>958</fpage>.</mixed-citation></ref><ref id="deo2400-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="deo2400-cit-0047">
<string-name>
<surname>Hasegawa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kanemitsu</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Association between occurrence of multiple white and flat elevated gastric lesions and oral proton pump inhibitor intake</article-title>. <source>Clin Endosc</source>
<year>2024</year>; <volume>57</volume>: <fpage>65</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">37157963</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="deo2400-cit-0048">
<string-name>
<surname>Hasegawa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ihara</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Magnified endoscopic findings of multiple white flat lesions: A new subtype of gastric hyperplastic polyps in the stomach</article-title>. <source>Clin Endosc</source>
<year>2018</year>; <volume>51</volume>: <fpage>558</fpage>&#x02013;<lpage>562</lpage>.<pub-id pub-id-type="pmid">30458604</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="deo2400-cit-0049">
<string-name>
<surname>Adachi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mishiro</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Okada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Prevalence of multiple white and flat elevated lesions in individuals undergoing a medical checkup</article-title>. <source>Intern Med</source>
<year>2018</year>; <volume>57</volume>: <fpage>1213</fpage>&#x02013;<lpage>1218</lpage>.<pub-id pub-id-type="pmid">29279510</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="deo2400-cit-0050">
<string-name>
<surname>Majima</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Muraki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shimamoto</surname>
<given-names>T</given-names>
</string-name>. <article-title>Multiple white and flat elevated lesions observed in the stomach: A prospective study of clinical characteristics and risk factors</article-title>. <source>Intern Med</source>
<year>2018</year>; <volume>57</volume>: <fpage>2613</fpage>&#x02013;<lpage>2619</lpage>.<pub-id pub-id-type="pmid">29709960</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="deo2400-cit-0051">
<string-name>
<surname>Miyamoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matsuno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kato</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan</article-title>. <source>Am J Gastroenterol</source>
<year>2017</year>; <volume>112</volume>: <fpage>1899</fpage>&#x02013;<lpage>1901</lpage>.<pub-id pub-id-type="pmid">29215611</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="deo2400-cit-0052">
<string-name>
<surname>Takahari</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ohtani</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Proton Pump Inhibitor Induction of Gastric Cobblestone&#x02010;like Lesions in the Stomach</article-title>. <source>Intern Med</source>
<year>2017</year>; <volume>56</volume>: <fpage>2699</fpage>&#x02013;<lpage>2703</lpage>.<pub-id pub-id-type="pmid">28924108</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="deo2400-cit-0053">
<string-name>
<surname>Hatano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kamada</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Factors associated with gastric black spot, white flat elevated mucosa, and cobblestone&#x02010;like mucosa: A cross&#x02010;sectional study</article-title>. <source>Digestion</source>
<year>2018</year>; <volume>98</volume>: <fpage>185</fpage>&#x02013;<lpage>193</lpage>.<pub-id pub-id-type="pmid">29870991</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="deo2400-cit-0054">
<string-name>
<surname>Taylor</surname>
<given-names>IL</given-names>
</string-name>, <string-name>
<surname>Sells</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>McConnell</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Dockray</surname>
<given-names>GJ</given-names>
</string-name>. <article-title>Serum gastrin in patients with chronic renal failure</article-title>. <source>Gut</source>
<year>1980</year>; <volume>21</volume>: <fpage>1062</fpage>&#x02013;<lpage>1067</lpage>.<pub-id pub-id-type="pmid">7461464</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="deo2400-cit-0055">
<string-name>
<surname>Shinozaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Osawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Long&#x02010;term changes in serum gastrin levels during standard dose vonoprazan therapy</article-title>. <source>Scand J Gastroenterol</source>
<year>2022</year>; <volume>57</volume>: <fpage>1412</fpage>&#x02013;<lpage>1416</lpage>.<pub-id pub-id-type="pmid">35830502</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="deo2400-cit-0056">
<string-name>
<surname>Hatano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ayaki</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Black spot, a novel gastric finding potentially induced by proton pump inhibitors</article-title>. <source>Intern Med</source>
<year>2016</year>; <volume>55</volume>: <fpage>3079</fpage>&#x02013;<lpage>3084</lpage>.<pub-id pub-id-type="pmid">27803398</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="deo2400-cit-0057">
<string-name>
<surname>Adachi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Notsu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mishiro</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Relationship of <italic toggle="yes">Helicobacter pylori</italic> infection with gastric black spots shown by endoscopy</article-title>. <source>Intern Med</source>
<year>2019</year>; <volume>58</volume>: <fpage>767</fpage>&#x02013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">30449800</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="deo2400-cit-0058">
<string-name>
<surname>Yoshizaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Morisawa</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fujinami</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Propensity score matching analysis: Incidence and risk factors for &#x0201c;stardust&#x0201d; gastric mucosa, a novel gastric finding potentially induced by vonoprazan</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2021</year>; <volume>53</volume>: <fpage>94</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">33159407</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="deo2400-cit-0059">
<string-name>
<surname>Iwamuro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sakae</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Two cases of white globe appearance in non&#x02010;cancerous stomach</article-title>. <source>Ecancermedicalscience</source>
<year>2018</year>; <volume>12</volume>: <fpage>856</fpage>.<pub-id pub-id-type="pmid">30174718</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="deo2400-cit-0060">
<string-name>
<surname>Doyama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tsuyama</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The &#x0201c;white globe appearance&#x0201d; (WGA): A novel marker for a correct diagnosis of early gastric cancer by magnifying endoscopy with narrow&#x02010;band imaging (M&#x02010;NBI)</article-title>. <source>Endosc Int Open</source>
<year>2015</year>; <volume>3</volume>: <fpage>E120</fpage>&#x02013;<lpage>E124</lpage>.<pub-id pub-id-type="pmid">26135651</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="deo2400-cit-0061">
<string-name>
<surname>Nishiyama</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kobara</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ayaki</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>White spot, a novel endoscopic finding, may be associated with acid&#x02010;suppressing agents and hypergastrinemia</article-title>. <source>J Clin Med</source>
<year>2021</year>; <volume>10</volume>: <fpage>2625</fpage>.<pub-id pub-id-type="pmid">34203619</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="deo2400-cit-0062">
<string-name>
<surname>Luu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ben Ghezala</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bardou</surname>
<given-names>M</given-names>
</string-name>. <article-title>Editorial: &#x0201c;Stardust gastric mucosa&#x0201d; &#x02013; A novel and consistent marker of vonoprazan safety during follow&#x02010;up?</article-title>
<source>Aliment Pharmacol Ther</source>
<year>2021</year>; <volume>53</volume>: <fpage>196</fpage>&#x02013;<lpage>197</lpage>.<pub-id pub-id-type="pmid">33333602</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="deo2400-cit-0063">
<string-name>
<surname>Masuyama</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yoshitake</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Sasai</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk</article-title>. <source>Digestion</source>
<year>2015</year>; <volume>91</volume>: <fpage>30</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">25632914</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="deo2400-cit-0064">
<string-name>
<surname>Moayyedi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Bosch</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Safety of proton pump inhibitors based on a large, multi&#x02010;year, randomized trial of patients receiving rivaroxaban or aspirin</article-title>. <source>Gastroenterology</source>
<year>2019</year>; <volume>157</volume>: <fpage>682</fpage>&#x02013;<lpage>91.e2</lpage>.<pub-id pub-id-type="pmid">31152740</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="deo2400-cit-0065">
<string-name>
<surname>Haruma</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kinoshita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yao</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Randomised clinical trial: 3&#x02010;year interim analysis results of the VISION trial to evaluate the long&#x02010;term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis</article-title>. <source>BMC Gastroenterol</source>
<year>2023</year>; <volume>23</volume>: <fpage>139</fpage>.<pub-id pub-id-type="pmid">37127558</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="deo2400-cit-0066">
<string-name>
<surname>Brenna</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Waldum</surname>
<given-names>HL</given-names>
</string-name>. <article-title>Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: Establishment of a dose response relationship</article-title>. <source>Gut</source>
<year>1992</year>; <volume>33</volume>: <fpage>1303</fpage>&#x02013;<lpage>1306</lpage>.<pub-id pub-id-type="pmid">1446849</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="deo2400-cit-0067">
<string-name>
<surname>Walsh</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Role of gastrin as a trophic hormone</article-title>. <source>Digestion</source>
<year>1990</year>; <volume>47</volume> (Suppl <issue>1</issue>): <fpage>11</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">2093009</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="deo2400-cit-0068">
<string-name>
<surname>Shiotani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Katsumata</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gouda</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Hypergastrinemia in long&#x02010;term use of proton pump inhibitors</article-title>. <source>Digestion</source>
<year>2018</year>; <volume>97</volume>: <fpage>154</fpage>&#x02013;<lpage>162</lpage>.<pub-id pub-id-type="pmid">29310112</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="deo2400-cit-0069">
<string-name>
<surname>Lundell</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vieth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Nagy</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kahrilas</surname>
<given-names>PJ</given-names>
</string-name>. <article-title>Systematic review: The effects of long&#x02010;term proton pump inhibitor use on serum gastrin levels and gastric histology</article-title>. <source>Aliment Pharmacol Ther</source>
<year>2015</year>; <volume>42</volume>: <fpage>649</fpage>&#x02013;<lpage>663</lpage>.<pub-id pub-id-type="pmid">26177572</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="deo2400-cit-0070">
<string-name>
<surname>Kojima</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takeuchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sanomura</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Does the novel potassium&#x02010;competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross&#x02010;sectional study</article-title>. <source>Digestion</source>
<year>2018</year>; <volume>97</volume>: <fpage>70</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">29393198</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="deo2400-cit-0071">
<string-name>
<surname>Okahata</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nishi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Muraki</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>In vitro study of antral gastrin biosynthesis in response to weaning and corticosterone acetate in rats</article-title>. <source>Acta Endocrinol</source>
<year>1986</year>; <volume>111</volume>: <fpage>539</fpage>&#x02013;<lpage>545</lpage>.</mixed-citation></ref><ref id="deo2400-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="deo2400-cit-0072">
<string-name>
<surname>Tatsuguchi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hoshino</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kawami</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Influence of hypergastrinemia secondary to long&#x02010;term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa</article-title>. <source>Pathol Res Pract</source>
<year>2020</year>; <volume>216</volume>: <elocation-id>153113</elocation-id>.<pub-id pub-id-type="pmid">32853950</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="deo2400-cit-0073">
<string-name>
<surname>Iwakiri</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fujiwara</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Manabe</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Evidence&#x02010;based clinical practice guidelines for gastroesophageal reflux disease 2021</article-title>. <source>J Gastroenterol</source>
<year>2022</year>; <volume>57</volume>: <fpage>267</fpage>&#x02013;<lpage>285</lpage>.<pub-id pub-id-type="pmid">35226174</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="deo2400-cit-0074">
<string-name>
<surname>Nagao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yabuuchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Multiple gastric neuroendocrine tumors associated with long&#x02010;term use of a proton pump inhibitor and a potassium&#x02010;competitive acid blocker</article-title>. <source>Intern Med</source>. Published online: 27 Nov <year>2023</year>; DOI: <pub-id pub-id-type="doi">10.2169/internalmedicine.2857-23</pub-id>
</mixed-citation></ref><ref id="deo2400-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="deo2400-cit-0075">
<string-name>
<surname>Sato</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Imamura</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kaizaki</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Management and clinical outcomes of type I gastric carcinoid patients: Retrospective, multicenter study in Japan</article-title>. <source>Dig Endosc</source>
<year>2014</year>; <volume>26</volume>: <fpage>377</fpage>&#x02013;<lpage>384</lpage>.<pub-id pub-id-type="pmid">24188531</pub-id>
</mixed-citation></ref></ref-list></back></article>